D Crivellari
Overview
Explore the profile of D Crivellari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
958
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Allal A, Ares C, Dulguerov P, Tschanz E, Verdan C, Mhawech P, et al.
Strahlenther Onkol
. 2016 May;
180 Suppl 1:89-108.
PMID: 27137923
No abstract available.
2.
Muraro E, Comaro E, Talamini R, Turchet E, Miolo G, Scalone S, et al.
J Transl Med
. 2015 Jun;
13:204.
PMID: 26116238
Background: Locally advanced HER2-overexpressing breast cancer (BC) patients achieve a high rate of pathological complete responses (pCR) after neoadjuvant chemotherapy (NC). The apparently unaltered immune proficiency of these patients together...
3.
Mustacchi G, Puglisi F, Molino A, Crivellari D, Ghiotto C, Ferro A, et al.
Future Oncol
. 2015 Feb;
11(10):1493-500.
PMID: 25708426
Aim: This observational study investigates the use of adjuvant trastuzumab (AT) in HER2-positive breast cancer patients in a real-life setting, focusing on relapse and discontinuation rates. Patients & Methods: Data...
4.
Karlsson P, Cole B, Chua B, Price K, Lindtner J, Collins J, et al.
Ann Oncol
. 2012 Jul;
23(11):2852-2858.
PMID: 22776708
Background: Rates and risk factors of local, axillary and supraclavicular recurrences can guide patient selection and target for postmastectomy radiotherapy (PMRT). Patients And Methods: Local, axillary and supraclavicular recurrences were...
5.
Monfardini S, Basso U, Fiduccia P, Crivellari D, Molino A, Falci C
Br J Cancer
. 2012 Feb;
106(6):1247.
PMID: 22343620
No abstract available.
6.
Gori S, Montemurro F, Spazzapan S, Metro G, Foglietta J, Bisagni G, et al.
Ann Oncol
. 2011 Nov;
23(6):1436-41.
PMID: 22039084
Background: Preclinical data suggest that treatment with lapatinib reinduces sensitivity to trastuzumab in human epidermal growth factor receptor 2(HER2)-positive breast cancer cells. Patients And Methods: Between January 2007 and November...
7.
Biganzoli L, Di Vincenzo E, Jiang Z, Lichinitser M, Shen Z, Delva R, et al.
Ann Oncol
. 2011 Mar;
23(1):111-118.
PMID: 21444356
Background: There are limited data on treatment outcomes in the growing population of elderly patients with locally recurrent/metastatic breast cancer (LR/mBC). To gain information on first-line bevacizumab combined with chemotherapy...
8.
Karlsson P, Sun Z, Braun D, Price K, Castiglione-Gertsch M, Rabaglio M, et al.
Ann Oncol
. 2011 Feb;
22(10):2216-26.
PMID: 21325445
Background: The International Breast Cancer Study Group Trial VIII compared long-term efficacy of endocrine therapy (goserelin), chemotherapy [cyclophosphamide, methotrexate and fluorouracil (CMF)], and chemoendocrine therapy (CMF followed by goserelin) for...
9.
Aebi S, Sun Z, Braun D, Price K, Castiglione-Gertsch M, Rabaglio M, et al.
Ann Oncol
. 2011 Feb;
22(9):1981-1987.
PMID: 21282282
Background: The benefit of adjuvant chemotherapy in postmenopausal patients with estrogen receptor (ER)-positive lymph node-negative breast cancer is being reassessed. Patients And Methods: After stratification by ER status, 1669 postmenopausal...
10.